Phase I study of 3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule

Annals of Oncology

Volumn 8, Issue 8, 1997, Pages 807-809

  Ratain, M J ^a   Skoog, L A ^a   O'Brien, S M ^a   Cooper, N ^a   Schilsky, R L ^a   Vogelzang, N J ^a   Gerber, M ^b   Narang, P K ^b   Nicol, S J ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Pharmacia   (United States)

Author keywords

Methoxymorpholinodoxorubicin; Phase I; Therapeutics oncology

Indexed keywords

NEMORUBICIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LYMPHOMA; MALE; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0030930008     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008258911785     Document Type: Article

References (7)

1. Ripamonti M, Pezzoni G, Pesenti E et al. In vivo antitumor activity of FCE 23762, a methoxy morpholinyl derivative of doxorubicin active on doxorubicin-resistant tumor cells. Br J Cancer 1992; 65: 703-7.
2. Grandi M, Pezzoni G, Ballinari D et al. Novel anthracycline analogs. Cancer Treat Rev 1990; 17: 133-8.
3. Capranico G, Supino R, Binaschi M et al. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol Pharmacol 1994; 45: 908-15.
4. Lau DHM, Duran GE, Lewis AD et al. Metabolic conversion of methoxymorpholinyl doxorubicin: From a DNA strand breaker to a DNA cross-linker. Br J Cancer 1994; 70: 79-84.
5. Kuhl JS, Duran GE, Chao NJ et al. Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemother Pharmacol 1993; 33: 10-6.
6. Vasey PA, Bissett D, Strolin-Benedetti M et al. Phase I clinical and pharmacokinetic study of 3′-deamino-3′-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762). Cancer Res 1995; 55: 2090-6.
7. Groen HJM, Droz JP, Hanauske AR et al. A feasibility study with FCE 23762 every 4 weeks in adults with solid tumors. Proc Am Soc Clin Oncol 1995; 14: 468.